Exclusive: Cell and gene therapy CDMO VintaBio emerges onto the scene with $64M and a new CEO
A contract manufacturer is emerging from stealth with cash on hand and a new CEO — and jumping right into the busy cell and gene therapy production space.
On Tuesday, VintaBio announced that it has raised $64 million in a funding round and has brought in David Radspinner to lead the outfit as CEO. VintaBio is a Philadelphia-based CDMO serving the cell and gene therapy market. It was started around three years ago by Junwei Sun and Shangzhen Zhou, who helped develop the first viral vectors used in the first CAR-T to treat cancer as well as early gene therapies while at the University of Pennsylvania.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters